Product Name:
POU2F1-pS385
Product Number:
ab-pn643
Target Full Name: POU domain, class 2, transcription factor 1
Target Alias: NF-A1; OCT1; Oct-1; Octamer-binding transcription factor 1; OTF1; OTF-1; PO21; PO2F1; POU class 2 homeobox 1
Product Type Specific: POU2F1 phosphosite-specific antibody
Antibody Code: PN643
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S385
Protein UniProt: P14859
Protein SigNET: POU2F1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human POU2F1
Antibody Immunogen Sequence: KKRT(pS)IET(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues K381 to T388. S385 phosphorylation inhibits transcriptional activity by inhibiting DNA binding. This is a major site of in vivo phosphorylation of POU2F1 (≥13 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus). POU2F1 is known to be phosphorylated at this site in vitro by PKACa (PRKACA).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog.
Scientific Background: POU2F1 (POU domain, class 2, transcription factor 1; Oct-1) is a ubiquitous, nuclear transcription factor that belongs to the POU transcription factor family, Class-2 subfamily. It binds to the octamer motif (5'-ATTTGCAT-3'). It functions as a DNA-binding transcription activator (RNA polymerase II-specific) and binds to specific promoter regions. It regulates gene expression, including the genes for some small nuclear RNAs (snRNA) and histone H2B and immunoglobulins. It is involved in stress responses, immune modulation, and metabolic regulation. It acts as a pro-oncogenic factor in various cancers. It functions as a DNA-binding transcription activator (RNA polymerase II-specific) and binds to specific promoter regions. It modulates transcription transactivation by NR3C1, AR and PGR. In case of human herpes simplex virus (HSV) infection, POU2F1 forms a multiprotein-DNA complex with the viral transactivator protein VP16 and HCFC1 thereby enabling the transcription of the viral immediate early genes. It partners with cofactors like OCA-S to regulate histone transcription, and with HCF1 and VP16 during herpes simplex virus infection to initiate viral genes. It is known to be involved in the AKT signaling pathway and linked to stress response mechanisms. Isoform 2 is lymphocyte-specific. POU2F1 is often overexpressed in cancers (e.g., HCC, gastric cancer, breast cancer), and acts as a potential prognostic marker and promoter of tumour growth, viability, and epithelial-mesenchymal transition (EMT). This description may include information annotated by UniProt and/or Google AI.

